| pubmed-article:11325646 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11325646 | lifeskim:mentions | umls-concept:C0026764 | lld:lifeskim |
| pubmed-article:11325646 | lifeskim:mentions | umls-concept:C0039736 | lld:lifeskim |
| pubmed-article:11325646 | lifeskim:mentions | umls-concept:C0011777 | lld:lifeskim |
| pubmed-article:11325646 | lifeskim:mentions | umls-concept:C0085405 | lld:lifeskim |
| pubmed-article:11325646 | lifeskim:mentions | umls-concept:C1704419 | lld:lifeskim |
| pubmed-article:11325646 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:11325646 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:11325646 | pubmed:dateCreated | 2001-4-30 | lld:pubmed |
| pubmed-article:11325646 | pubmed:abstractText | The immunomodulatory drug thalidomide can inhibit angiogenesis and induce apoptosis in experimental models. It can also induce marked and durable response in advanced myeloma patients. Thalidomide has been used at doses ranging from 200 to 800 mg with significant toxicity. No data are available on the impact of low-dose thalidomide plus dexamethasone as salvage therapy for relapsed patients. | lld:pubmed |
| pubmed-article:11325646 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11325646 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11325646 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11325646 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11325646 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11325646 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11325646 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:11325646 | pubmed:issn | 0390-6078 | lld:pubmed |
| pubmed-article:11325646 | pubmed:author | pubmed-author:PileriAA | lld:pubmed |
| pubmed-article:11325646 | pubmed:author | pubmed-author:BoccadoroMM | lld:pubmed |
| pubmed-article:11325646 | pubmed:author | pubmed-author:PalumboAA | lld:pubmed |
| pubmed-article:11325646 | pubmed:author | pubmed-author:GalloEE | lld:pubmed |
| pubmed-article:11325646 | pubmed:author | pubmed-author:PregnoPP | lld:pubmed |
| pubmed-article:11325646 | pubmed:author | pubmed-author:RufPP | lld:pubmed |
| pubmed-article:11325646 | pubmed:author | pubmed-author:TrioloSS | lld:pubmed |
| pubmed-article:11325646 | pubmed:author | pubmed-author:BertolaAA | lld:pubmed |
| pubmed-article:11325646 | pubmed:author | pubmed-author:BringhenSS | lld:pubmed |
| pubmed-article:11325646 | pubmed:author | pubmed-author:GiacconeLL | lld:pubmed |
| pubmed-article:11325646 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11325646 | pubmed:volume | 86 | lld:pubmed |
| pubmed-article:11325646 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11325646 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11325646 | pubmed:pagination | 399-403 | lld:pubmed |
| pubmed-article:11325646 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:11325646 | pubmed:meshHeading | pubmed-meshheading:11325646... | lld:pubmed |
| pubmed-article:11325646 | pubmed:meshHeading | pubmed-meshheading:11325646... | lld:pubmed |
| pubmed-article:11325646 | pubmed:meshHeading | pubmed-meshheading:11325646... | lld:pubmed |
| pubmed-article:11325646 | pubmed:meshHeading | pubmed-meshheading:11325646... | lld:pubmed |
| pubmed-article:11325646 | pubmed:meshHeading | pubmed-meshheading:11325646... | lld:pubmed |
| pubmed-article:11325646 | pubmed:meshHeading | pubmed-meshheading:11325646... | lld:pubmed |
| pubmed-article:11325646 | pubmed:meshHeading | pubmed-meshheading:11325646... | lld:pubmed |
| pubmed-article:11325646 | pubmed:meshHeading | pubmed-meshheading:11325646... | lld:pubmed |
| pubmed-article:11325646 | pubmed:meshHeading | pubmed-meshheading:11325646... | lld:pubmed |
| pubmed-article:11325646 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11325646 | pubmed:articleTitle | Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. | lld:pubmed |
| pubmed-article:11325646 | pubmed:affiliation | Divisione di Ematologia dell'Università di Torino, Azienda Ospedaliera S. Giovanni Battista, Torino, Italy. | lld:pubmed |
| pubmed-article:11325646 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11325646 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:11325646 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11325646 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11325646 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11325646 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11325646 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11325646 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11325646 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11325646 | lld:pubmed |
